The expression of IER3, a target gene of triacetylacetone proline (TTP), was decreased in HCC cells treated by MAPKAP2 (MK2) inhibitors, suggesting that IER3 may be one of the therapeutic targets for HCC. Here, IER3 is linked to hepatocellular carcinoma.